EUR 187.45
(0.83%)
Year | EBITDA | EBITDA Growth |
---|---|---|
2023 | 1.26 Billion EUR | -1.52% |
2022 | 1.16 Billion EUR | -32.99% |
2021 | 1.59 Billion EUR | 10.44% |
2020 | 1.3 Billion EUR | -4.72% |
2019 | 1.33 Billion EUR | -0.21% |
2018 | 1.4 Billion EUR | 10.15% |
2017 | 1.27 Billion EUR | 23.64% |
2016 | 1.08 Billion EUR | 24.0% |
2015 | 829 Million EUR | 38.17% |
2014 | 600 Million EUR | 10.29% |
2013 | 544 Million EUR | -12.54% |
2012 | 637 Million EUR | -16.62% |
2011 | 610 Million EUR | 2.05% |
2010 | 430 Million EUR | -44.41% |
2009 | 1 Billion EUR | 74.63% |
2008 | 270 Million EUR | 6.96% |
2007 | 545 Million EUR | 0.28% |
2006 | 678 Million EUR | 18.98% |
2005 | 503 Million EUR | -28.88% |
2004 | 355 Million EUR | 4.01% |
2003 | 797.61 Million EUR | -15.45% |
2002 | 829.74 Million EUR | 0.0% |
Year | EBITDA | EBITDA Growth |
---|---|---|
2024 Q2 | 644 Million EUR | 0.0% |
2023 Q2 | 794 Million EUR | 0.0% |
2023 FY | - EUR | -1.52% |
2023 Q4 | 552 Million EUR | 0.0% |
2022 FY | - EUR | -32.99% |
2022 Q2 | 809 Million EUR | 0.0% |
2022 Q4 | 440 Million EUR | 0.0% |
2021 Q2 | 851 Million EUR | 0.0% |
2021 FY | - EUR | 10.44% |
2021 Q4 | 774 Million EUR | 0.0% |
2020 FY | - EUR | -4.72% |
2020 Q4 | 653 Million EUR | 0.0% |
2020 Q2 | 779 Million EUR | 0.0% |
2019 Q4 | 689 Million EUR | 0.0% |
2019 FY | - EUR | -0.21% |
2019 Q2 | 708 Million EUR | 0.0% |
2018 Q2 | 796 Million EUR | 0.0% |
2018 FY | - EUR | 10.15% |
2017 Q4 | 593 Million EUR | 0.0% |
2017 FY | - EUR | 23.64% |
2017 Q2 | 678 Million EUR | 0.0% |
2016 FY | - EUR | 24.0% |
2016 Q2 | 546 Million EUR | 0.0% |
2015 FY | - EUR | 38.17% |
2015 Q4 | 378 Million EUR | 0.0% |
2015 Q2 | 451 Million EUR | 0.0% |
2014 Q4 | 291 Million EUR | 0.0% |
2014 FY | - EUR | 10.29% |
2014 Q2 | 309 Million EUR | 0.0% |
2013 Q4 | 254 Million EUR | 0.0% |
2013 Q2 | 290 Million EUR | 0.0% |
2013 FY | - EUR | -12.54% |
2012 Q3 | 159.25 Million EUR | 0.0% |
2012 FY | - EUR | -16.62% |
2012 Q4 | 173 Million EUR | 8.63% |
2012 Q2 | 159.25 Million EUR | 0.0% |
2012 Q1 | 159.25 Million EUR | 0.0% |
2011 Q1 | 173.5 Million EUR | 0.0% |
2011 Q2 | 173.5 Million EUR | 0.0% |
2011 Q3 | 173.5 Million EUR | 0.0% |
2011 Q4 | 159.25 Million EUR | -8.21% |
2011 FY | - EUR | 2.05% |
2010 Q4 | 173.5 Million EUR | 48.61% |
2010 Q2 | 116.75 Million EUR | 0.0% |
2010 Q3 | 116.75 Million EUR | 0.0% |
2010 Q1 | 116.75 Million EUR | 0.0% |
2010 FY | - EUR | -44.41% |
2009 Q4 | 116.75 Million EUR | -58.41% |
2009 FY | - EUR | 74.63% |
2009 Q2 | 280.75 Million EUR | 0.0% |
2009 Q3 | 280.75 Million EUR | 0.0% |
2009 Q1 | 280.75 Million EUR | 0.0% |
2008 Q3 | 94.25 Million EUR | 0.0% |
2008 FY | - EUR | 6.96% |
2008 Q1 | 94.25 Million EUR | 0.0% |
2008 Q2 | 94.25 Million EUR | 0.0% |
2008 Q4 | 280.75 Million EUR | 197.88% |
2007 Q4 | 94.25 Million EUR | -31.08% |
2007 FY | - EUR | 0.28% |
2007 Q3 | 136.75 Million EUR | 0.0% |
2007 Q2 | 136.75 Million EUR | 0.0% |
2007 Q1 | 136.75 Million EUR | 0.0% |
2006 Q3 | 169 Million EUR | 0.0% |
2006 Q4 | 136.75 Million EUR | -19.08% |
2006 Q2 | 169 Million EUR | 0.0% |
2006 FY | - EUR | 18.98% |
2006 Q1 | 169 Million EUR | 0.0% |
2005 Q4 | 169 Million EUR | -28.01% |
2005 FY | - EUR | -28.88% |
2005 Q2 | 234.75 Million EUR | 0.0% |
2005 Q3 | 234.75 Million EUR | 0.0% |
2005 Q1 | 234.75 Million EUR | 0.0% |
2004 Q2 | 206.57 Million EUR | 0.0% |
2004 FY | - EUR | 4.01% |
2004 Q1 | 206.57 Million EUR | 0.0% |
2004 Q3 | 206.57 Million EUR | 0.0% |
2004 Q4 | 234.75 Million EUR | 13.64% |
2003 Q4 | 206.57 Million EUR | 4.94% |
2003 Q3 | 196.85 Million EUR | 0.0% |
2003 Q1 | 196.85 Million EUR | 0.0% |
2003 Q2 | 196.85 Million EUR | 0.0% |
2003 FY | - EUR | -15.45% |
2002 Q3 | 204.89 Million EUR | 0.0% |
2002 Q2 | 204.89 Million EUR | 0.0% |
2002 Q1 | 204.89 Million EUR | 0.0% |
2002 FY | - EUR | 0.0% |
2002 Q4 | 196.85 Million EUR | -3.92% |
2001 Q4 | 204.89 Million EUR | 0.0% |
Name | EBITDA | EBITDA Difference |
---|---|---|
ABIONYX Pharma SA | -3.29 Million EUR | 38671.429% |
ABIVAX Société Anonyme | -133.2 Million EUR | 1052.653% |
Adocia SA | -22.73 Million EUR | 5682.439% |
Aelis Farma SA | -6.34 Million EUR | 20093.698% |
Biophytis S.A. | -13.8 Million EUR | 9292.988% |
Advicenne S.A. | -6.24 Million EUR | 20423.511% |
genOway Société anonyme | 6.35 Million EUR | -19881.892% |
IntegraGen SA | -52.5 Thousand EUR | 2417104.743% |
Medesis Pharma S.A. | -3.84 Million EUR | 33104.897% |
Neovacs S.A. | -8.44 Million EUR | 15118.558% |
NFL Biosciences SA | -4.04 Million EUR | 31438.734% |
Plant Advanced Technologies SA | 72.53 Thousand EUR | -1749520.847% |
Quantum Genomics Société Anonyme | -2.87 Million EUR | 44262.479% |
Sensorion SA | -22.31 Million EUR | 5787.062% |
Theranexus Société Anonyme | -7.38 Million EUR | 17278.29% |
TME Pharma N.V. | -5.07 Million EUR | 25119.716% |
Valbiotis SA | -6.95 Million EUR | 18345.866% |
TheraVet SA | -517.33 Thousand EUR | 245395.127% |
Valerio Therapeutics Société anonyme | -18.91 Million EUR | 6808.606% |
argenx SE | -199.5 Million EUR | 736.071% |
BioSenic S.A. | -6.79 Million EUR | 18772.749% |
Celyad Oncology SA | -7.76 Million EUR | 16446.773% |
DBV Technologies S.A. | -79.53 Million EUR | 1695.608% |
Galapagos NV | 51.03 Million EUR | -2386.431% |
Genfit S.A. | -28.05 Million EUR | 4623.903% |
GeNeuro SA | -14.31 Million EUR | 8963.155% |
Hyloris Pharmaceuticals SA | -14.98 Million EUR | 8571.295% |
Innate Pharma S.A. | -7.57 Million EUR | 16845.843% |
Inventiva S.A. | -101.84 Million EUR | 1345.974% |
MaaT Pharma SA | -19.74 Million EUR | 6528.571% |
MedinCell S.A. | -20.04 Million EUR | 6430.44% |
Nanobiotix S.A. | -34.01 Million EUR | 3830.268% |
Onward Medical N.V. | -35.23 Million EUR | 3701.635% |
Oryzon Genomics S.A. | -4.43 Million EUR | 28723.901% |
OSE Immunotherapeutics SA | -23.26 Million EUR | 5554.311% |
Oxurion NV | -16.72 Million EUR | 7685.63% |
Pharming Group N.V. | 4.98 Million EUR | -25376.991% |
Poxel S.A. | -12.17 Million EUR | 10519.575% |
GenSight Biologics S.A. | -21.73 Million EUR | 5939.853% |
Transgene SA | -27.02 Million EUR | 4795.826% |
Financière de Tubize SA | 184.57 Thousand EUR | -687440.296% |
Valneva SE | -64.51 Million EUR | 2066.923% |
Vivoryon Therapeutics N.V. | -28.35 Million EUR | 4575.717% |